相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells
Emeric Limagne et al.
CANCER CELL (2022)
A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs
Zuzana Tatarova et al.
NATURE BIOTECHNOLOGY (2022)
Isoforms of the p53 Family and Gastric Cancer: A Menage a Trois for an Unfinished Affair
Anais Blanchet et al.
CANCERS (2021)
Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers
Sandra Ortiz-Cuaran et al.
FRONTIERS IN ONCOLOGY (2021)
Antitumor Immune Response Triggered by Metal-Based Photosensitizers for Photodynamic Therapy: Where Are We?
Alain C. Jung et al.
PHARMACEUTICS (2021)
Cetuximab in locally advanced head and neck squamous cell carcinoma: Biological mechanisms involved in efficacy, toxicity and resistance
Elena Muraro et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma
Areeg Elmusrati et al.
INTERNATIONAL JOURNAL OF ORAL SCIENCE (2021)
Current Clinical and Pre-Clinical Imaging Approaches to Study the Cancer-Associated Immune System
Christopher G. Mueller et al.
FRONTIERS IN IMMUNOLOGY (2021)
The TP53-Related Signature Predicts Immune Cell Infiltration, Therapeutic Response, and Prognosis in Patients With Esophageal Carcinoma
Hongpan Zhang et al.
FRONTIERS IN GENETICS (2021)
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Lorenzo Galluzzi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation
Yuhui Yang et al.
FRONTIERS IN IMMUNOLOGY (2020)
Tumor-Associated Macrophages in Tumor Immunity
Yueyun Pan et al.
FRONTIERS IN IMMUNOLOGY (2020)
Head and neck squamous cell carcinoma
Daniel E. Johnson et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer
Jessica J. Miller et al.
CHEMICAL SOCIETY REVIEWS (2020)
Anticancer activity of ruthenium and osmium cyclometalated compounds: identification of ABCB1 and EGFR as resistance mechanisms
Cynthia Licona et al.
INORGANIC CHEMISTRY FRONTIERS (2020)
Clinical update on head and neck cancer: molecular biology and ongoing challenges
Elham Alsahafi et al.
CELL DEATH & DISEASE (2019)
Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas
Lawrence A. Donehower et al.
CELL REPORTS (2019)
Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on EREG-Driven Oncogenic Addiction
Sylvie Job et al.
CANCERS (2019)
Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer
So-Jin Park et al.
ORAL ONCOLOGY (2019)
Constitutive or Induced HIF-2 Addiction is Involved in Resistance to Anti-EGFR Treatment and Radiation Therapy in HNSCC
Pierre Coliat et al.
CANCERS (2019)
Bifunctional ligand design for modulating mutant p53 aggregation in cancer
Jessica J. Miller et al.
CHEMICAL SCIENCE (2019)
Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
Junjie Wu et al.
CANCER LETTERS (2018)
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy
Ryuma Tokunaga et al.
CANCER TREATMENT REVIEWS (2018)
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
Lorenzo Galluzzi et al.
CELL DEATH AND DIFFERENTIATION (2018)
Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer
Kyle Knickelbein et al.
ONCOGENE (2018)
Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments
Benjamin Solomon et al.
SEMINARS IN CANCER BIOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer
Zehang Jiang et al.
TRANSLATIONAL ONCOLOGY (2018)
The role of p53 in cancer drug resistance and targeted chemotherapy
Karin Hientz et al.
ONCOTARGET (2017)
Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity
Gang Guo et al.
CANCER RESEARCH (2017)
YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins
Silvia Di Agostino et al.
EMBO REPORTS (2016)
Caspases Connect Cell-Death Signaling to Organismal Homeostasis
Lorenzo Galluzzi et al.
IMMUNITY (2016)
TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response
Ge Zhou et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2016)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert et al.
LANCET ONCOLOGY (2016)
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
Chiara Pozzi et al.
NATURE MEDICINE (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Molecular and Cellular Mechanisms of Antitumor Immune Response Activation by Dendritic Cells
O. V. Markov et al.
ACTA NATURAE (2016)
Synergistic Inhibitory Effects of Cetuximab and Cisplatin on Human Colon Cancer Cell Growth via Inhibition of the ERK-Dependent EGF Receptor Signaling Pathway
Dong Ju Son et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma
Ning Jiang et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Antonella Sistigu et al.
NATURE MEDICINE (2014)
Consensus guidelines for the detection of immunogenic cell death
Oliver Kepp et al.
ONCOIMMUNOLOGY (2014)
Comparative Analysis of Tumor-Infiltrating Lymphocytes in a Syngeneic Mouse Model of Oral Cancer
Nancy P. Judd et al.
OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2012)
p53 Modulates Acquired Resistance to EGFR Inhibitors and Radiation
Shyhmin Huang et al.
CANCER RESEARCH (2011)
Induction of Immunogenic Apoptosis by Blockade of Epidermal Growth Factor Receptor Activation with a Specific Antibody
Greta Garrido et al.
JOURNAL OF IMMUNOLOGY (2011)
Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress
I. Martins et al.
ONCOGENE (2011)
HMGB1 and RAGE in Inflammation and Cancer
Gary P. Sims et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 28 (2010)
Regulatory T cells: immune suppression and beyond
Yisong Y. Wan
CELLULAR & MOLECULAR IMMUNOLOGY (2010)
Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells
L. Sauer et al.
ONCOGENE (2010)
P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab
S. Bouali et al.
CANCER GENE THERAPY (2009)
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death
Theocharis Panaretakis et al.
EMBO JOURNAL (2009)
Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial
Fernando Rivera et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Involvement of N-terminally truncated variants of p73, ΔTAp73, in head and neck squamous cell cancer
Laetitia Faridoni-Laurens et al.
CELL CYCLE (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
NATURE MEDICINE (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
p63 and p73 - Life and death in squamous cell carcinoma
James W. Rocco et al.
CELL CYCLE (2006)
p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis
JW Rocco et al.
CANCER CELL (2006)
The three Es of cancer immunoediting
GP Dunn et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain
C Gaiddon et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
分享论文
